Results 131 to 140 of about 41,944 (264)

TONSL Promotes Hepatocellular Carcinoma Progression by Inhibiting Apoptosis Through Homologous Recombination Repair

Cancer Science, EarlyView.
In hepatocellular carcinoma, the 8q24.3 locus is frequently amplified and is associated with tumor‐specific overexpression of TONSL. TONSL promotes homologous recombination repair through RAD51, limits γH2AX accumulation and apoptosis, supports tumor growth, and its loss increases sensitivity to poly (ADP‐ribose) polymerase (PARP) inhibition.
Akinori Tsujimoto, Hajime Otsu, Takashi Ofuchi, Tomohiko Ikehara, Kosuke Hirose, Shohei Shibuta, Kazuki Omachi, Yu Takahashi, Yuya Ono, Satoshi Higuchi, Takanari Tatsumi, Kiyotaka Hosoda, Qingjiang Hu, Yusuke Yonemura, Takaaki Masuda, Masayuki Sho, Koshi Mimori   +16 more
wiley   +1 more source

Pharmacokinetic boosting of olaparib: Study protocol of a multicentre, open-label, randomised, non-inferiority trial (PROACTIVE-B)

Contemporary Clinical Trials Communications
Background: Pharmacokinetic (PK) boosting is the intentional use of a drug-drug interaction to enhance systemic drug exposure. PK boosting of the anticancer drug olaparib, a CYP3A-substrate, has the potential to reduce PK variability, side effects and ...
Joanneke K. Overbeek, Niels A.D. Guchelaar, Ma Ida Mohmaed Ali, Muriëlle Sark, Carolien Hovenier, Wietske Kievit, Marjolijn J.L. Ligtenberg, Petronella B. Ottevanger, Haiko J. Bloemendal, Stijn L.W. Koolen, Ron H.J. Mathijssen, Ingrid A. Boere, Alwin D.R. Huitema, Gabe S. Sonke, Frans L. Opdam, Rob ter Heine, Nielka P. van Erp   +16 more
doaj   +1 more source

EWS/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing Sarcoma [PDF]

, 2018
Many cancer types are driven by oncogenic transcription factors that have been difficult to drug. Transcriptional inhibitors, however, may offer inroads into targeting these cancers.
Abraham, Brian J., Alexe, Gabriela, Benes, Cyril H., Chowdhury, Dipanjan, Conway, Amy Saur, Dharia, Neekesh V., Gray, Nathanael S., Iniguez, Amanda Balboni, Kalev, Peter, Kwiatkowski, Nicholas, Leggett, Alan, Mora, Jaume, Stegmaier, Kimberly, Stolte, Björn, Wang, Emily Jue, Young, Richard A, Zhang, Tinghu   +16 more
core   +1 more source

Results of a randomised Phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer

British Journal of Cancer
OCTOVA compared the efficacy of olaparib (O) versus weekly paclitaxel (wP) or olaparib + cediranib (O + C) in recurrent ovarian cancer (OC). The main aim of the OCTOVA trial was to determine the progression-free survival (PFS) of olaparib (O) versus the ...
S. Nicum, N. McGregor, Rachel Austin, L. Collins, Susan Dutton, I. McNeish, R. Glasspool, M. Hall, René Roux, Agnieszka Michael, A. Clamp, G. Jayson, R. Kristeleit, Susana Banerjee, Anita Mansouri   +14 more
semanticscholar   +1 more source

Automodification of N‐terminal serine residues facilitates PARP2 release from DNA

The FEBS Journal, EarlyView.
PARP2 is involved in detecting DNA damage and its N‐terminal role is largely unknown. Based on biochemical and biophysical data, our findings suggest that in the presence of HPF1, N‐terminal serine 8 and 73 are enriched in auto‐ADP‐ribosylation. Our results provide insight into the mechanistic role of PARP2 N‐terminus in the PARylation‐dependent ...
Saurabh Singh Dhakar, Albert Galera‐Prat, Jin Cai, Julia Preisser, Tiila‐Riikka Kiema, Andreas Ladurner, Lari Lehtiö   +6 more
wiley   +1 more source

Opposing roles of DGAT‐mediated lipid droplet biogenesis in the regulation of ferroptosis sensitivity

The FEBS Journal, EarlyView.
Ferroptosis is driven by unrestricted peroxidation of polyunsaturated fatty acyl (PUFA) chains in membrane phospholipids. In triple‐negative breast cancer cells, lipid droplets (LDs) sequester dietary PUFAs, limiting their incorporation into membrane phospholipids, preventing mitochondrial damage, and reducing lipid peroxidation and ferroptosis.
Ana Kump, Leja Perne, Špela Koren, Eva Jarc Jovičić, Nastja Feguš, Carina Pinto Kozmus, Michele Wölk, Kristyna Brejchova, Maria Fedorova, Ondrej Kuda, Toni Petan   +10 more
wiley   +1 more source

Potentiation of peptide receptor radionuclide therapy by the PARP inhibitor olaparib [PDF]

, 2016
Metastases expressing tumor-specific receptors can be targeted and treated by binding of radiolabeled peptides (peptide receptor radionuclide therapy or PRRT).
Beerens, C.E.M.T. (Cecile), Doukas, M. (Michael), Eijck, C.H.J. (Casper) van, Gent, D.C. (Dik) van, Jong, M. (Marcel) de, Nonnekens, J. (Julie), Suker, M. (Mustafa), van Kranenburg, M. (Melissa)   +7 more
core   +1 more source

Pharmacokinetic Drug–Drug Interaction Potential of Oral Anticancer Drugs

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1614-1627, June 2026.
Drug–drug interaction (DDI) management is critical for safe and effective use of oral anticancer drugs (OADs). Our study objectives were to (i) compile clinically relevant pharmacokinetic (PK) DDI mechanisms for OADs and (ii) assess the prevalence of PK potential DDIs (PDDIs) in patients with advanced solid cancers.
Fatimah Alhurayri, Islam R. Younis, Shadia I. Jalal, Theodore F. Logan, Rohan Maniar, Steven M. Bray, Sara K. Quinney, Zeruesenay Desta, Todd C. Skaar, James E. Tisdale, Tyler Shugg   +10 more
wiley   +1 more source

Clinical trial of safety and antitumor activity of farletuzumab ecteribulin in patients with platinum‐resistant ovarian cancer: Phase I expansion results

International Journal of Gynecology &Obstetrics, Volume 173, Issue 3, Page 1334-1342, June 2026.
Abstract Objective In the dose‐escalation part of Study 101, which included multiple tumor types, objective responses were observed in 10 of 22 patients across multiple dose levels of farletuzumab ecteribulin (FZEC). We explored the safety/antitumor activity of FZEC in patients with platinum‐resistant ovarian cancer (PROC) from the Study 101 expansion ...
Kan Yonemori, Mayu Yunokawa, Koji Matsumoto, Kazuhiro Takehara, Kosei Hasegawa, Yasuyuki Hirashima, Hidenori Kato, Hiroki Ikezawa, Yohei Otake, Wataru Yusa, Takuma Miura, Shin Nishio   +11 more
wiley   +1 more source

Organoids: From Bench to Bedside Applications

MedComm, Volume 7, Issue 6, June 2026.
Organoids, as a groundbreaking biomedical research platform, utilize adult stem cells (ASCs), embryonic stem cells (ESCs), and induced pluripotent stem cells (iPSCs) as sources. By integrating specific growth and differentiation signals within an extracellular matrix (e.g., Matrigel), organoids guide cells to self‐assemble into three‐dimensional ...
Kelin Li, Rui Cao, Maochen Li, Zichao Tian, Huahao Fan, Bixia Hong, Xiaojuan Liu   +6 more
wiley   +1 more source